Of these seven Phase III studies two are open and enrolling, and five are planned to begin by the end of 2008. These trials involve three different compounds: Sutent, axitinib and CP-751,871, and will focus on four types of cancers – hepatocelluar, non-small cell lung cancer, renal cell carcinoma and prostate cancer.
Pfizer also said that it has 22 oncology compounds in a total of 232 ongoing or planned, sponsored, oncology clinical studies.
Charles Baum, vice president of global research and development at Pfizer, said: “We are seeing our sustained efforts in oncology mature as our development programs continue to advance into late-stage clinical trials.”